BPG is committed to discovery and dissemination of knowledge
Featured Articles
6/17/2022 6:23:41 AM | Browse: 565 | Download: 1318
Publication Name World Journal of Orthopedics
Manuscript ID 75682
Country Greece
ISSN 2218-5836 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Orthopedics
Manuscript Type Minireviews
Article Title Topical use of tranexamic acid: Are there concerns for cytotoxicity?
Manuscript Source Unsolicited Manuscript
All Author List Ioannis Gkiatas, Aristeidis-Panagiotis Kontokostopoulos, Spyridon E Tsirigkakis, Ioannis Kostas-Agnantis, Ioannis Gelalis, Anastasios Korompilias and Emilios Pakos
Funding Agency and Grant Number
Corresponding Author Aristeidis-Panagiotis Kontokostopoulos, MD, Academic Research, Department of Orthopaedic Surgery, University of Ioannina, Stavrou Niarchou, Ioannina 45500, Epirus, Greece. ariskontok9@gmail.com
Key Words Tranexamic acid; Topical use; Cytotoxicity; Orthopaedic surgery
Core Tip Tranexamic acid (TXA) is an antifibrinolytic agent and is associated with decreased blood loss in surgical procedures. It is widely used in major orthopaedic procedures in order to decrease blood transfusion needs. TXA can be administered intravenously; however, topical administration of the drug increases concentration at the operative site. There are concerns that this increased concentration may cause toxicity in the cartilage tissue. In this review, we present the recent literature regarding the cytotoxic effects of the topical administration of TXA.
Publish Date 2022-06-17 03:54
Citation Gkiatas I, Kontokostopoulos AP, Tsirigkakis SE, Kostas-Agnantis I, Gelalis I, Korompilias A, Pakos E. Topical use of tranexamic acid: Are there concerns for cytotoxicity? World J Orthop 2022; 13(6): 555-563
URL https://www.wjgnet.com/2218-5836/full/v13/i6/555.htm
DOI https://dx.doi.org/10.5312/wjo.v13.i6.555
Full Article (PDF) WJO-13-555.pdf
Full Article (Word) WJO-13-555.docx